Evergreen Talk Series: Combination of Linagliptin and Dapagliflozin in T2DM with multiple episodes of hypoglycemia
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi...
Presenting the EVERGREEN Range
The Evergreen Duo
In people with uncontrolled diabetes, with HbA1c ≥ 8.0%
The Evergreen Gliptin
In People with Uncontrolled Diabetes
The Evergreen Start
In Drug Naive T2DM
Benefits
Ex|
Simplifies T2DM Care1
94.1% of HCPs confirms efficacy in diverse T2DM profile
Effective in Asians1
78.5% of HCPs confirm efficacy in the Asian population
Monotherapy & Combination Use3,6
Can be used effectively & safely as monotherapy and with other anti-hyperglycemic agents
Benefits Across BMI in RWE3
Consistently lowers glucose in T2DM, regardless of BMI
Effective for all ages T2DM2
Effectively reduces HbA1c and is well tolerated in T2DM patients
Robust Safety Evidence1
97.1% of Indian HCPs confirm cardiac and renal safety
Clinical Applicability
En|
Across Age Groups ( >18 years)5
BMI < 25 or ≥ 35 kg/m24
HbA1c 7% to ≥ 10%4
Proven CV Safety6
Proven Renal Safety6
No dose titration in Hepatic impairment7
Truly Once daily
Strong Roots of Evidence
Total scientific Evidence
0
Systematic Reviews
0
Randomized clinical Trials
0
Literature with Indian data
0
Evergreen Talk Series
Evergreen Talk Series: Position paper published in JAPI indicated that Linagliptin is simplifying T2DM management in a Wide Range of Patients
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi...
Evergreen Talk Series: Clinical Considerations for Linagliptin and its combinations with Metformin, Dapagliflozin
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi...
Evergreen Talk Series: Linagliptin and Dapagliflozin combination for T2DM with Cardiovascular risk or established ASCVD
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist....
Evergreen Talk Series: Clinical Benefits of Linagliptin and Dapagliflozin Combination in Type 2 Diabetes Management
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi...
Evergreen Talk Series: Clinical applicability of Linagliptin in T2DM across CKD spectrum and Dapagliflozin up to CKD stage 4
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi...
Evergreen Talk Series: Use of SGLT2i and DPP4i combination in T2DM patients with a history of Genitourinary Tract Infections
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I....
Evergreen Talk Series: How can Safety and Tolerability of Linagliptin and Dapagliflozin benefit diverse T2DM population?
Presenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I....
References
1) Mithal A. Ramachandran A. Bhattacharyya A, et al. Simplifying Type 2 DM Care with Linagliptin: A Position Paper. J Assoc Physicians India 2023.71(8):90-98
2) Del Prato S. Patel S, Crowe S. von Eynatton M, Efficacy and safety of linagliptin according to pabent baseline characteristics: A pooled analysis of three phase 3 triaks. Nutr Metab CardiovascDis. 2016 Oct;26(10):886-92. dok: 10.1016) numecd.2016.06,015. Epub 2016 Jut 1. PMID: 27484756.
3) Daisuke Yabe, Fumio Yamamoto, Seren S. Lund, Tomoo Okamura & Takashi Kadowaki (2022) Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study, Expert Opinion on Drug Safety, 21:10, 1303-1313, DOI: 10,1080/14740338 2022 2057948
4) McGit JB, Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Ther Adv Endocrinol Metab: 2012 Aug:3(4):113-24.
5) Ning, Guang, et al. "Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: a pooled analysis of randomized clinical trials." Advances in Therapy 34 (2017): 2150-2162.
6) Rosenstock, Julio, et al. "Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial." Jama 321.1 (2019): 69-79.
7) Inagaki, Nobuya, et al. "Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: a retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials." Journal of Diabetes and its Complications 30.8 (2016): 1622-1630.
2) Del Prato S. Patel S, Crowe S. von Eynatton M, Efficacy and safety of linagliptin according to pabent baseline characteristics: A pooled analysis of three phase 3 triaks. Nutr Metab CardiovascDis. 2016 Oct;26(10):886-92. dok: 10.1016) numecd.2016.06,015. Epub 2016 Jut 1. PMID: 27484756.
3) Daisuke Yabe, Fumio Yamamoto, Seren S. Lund, Tomoo Okamura & Takashi Kadowaki (2022) Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study, Expert Opinion on Drug Safety, 21:10, 1303-1313, DOI: 10,1080/14740338 2022 2057948
4) McGit JB, Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Ther Adv Endocrinol Metab: 2012 Aug:3(4):113-24.
5) Ning, Guang, et al. "Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: a pooled analysis of randomized clinical trials." Advances in Therapy 34 (2017): 2150-2162.
6) Rosenstock, Julio, et al. "Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial." Jama 321.1 (2019): 69-79.
7) Inagaki, Nobuya, et al. "Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: a retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials." Journal of Diabetes and its Complications 30.8 (2016): 1622-1630.
